BiotechTube
Torqur

Torqur

Zurich, Switzerland· Est.
torqur.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Torqur AG is a private, clinical-stage biotechnology company based in Zurich, Switzerland, developing targeted cancer therapies. Its core platform centers on creating a portfolio of disease-specific inhibitors of the PI3K/mTOR pathway, a key driver in many cancers. The lead asset, bimiralisib, is in Phase 2 development for actinic keratosis and other indications, with promising early clinical data. The company is a subsidiary of the Swiss Rockets incubator and is led by a board with deep expertise in oncology drug development and business.

OncologyDermatology

Technology Platform

Platform for discovery and development of small molecule inhibitors targeting the PI3K/Akt/mTOR intracellular signaling pathway, aiming for optimized pharmacokinetic and safety profiles.

Opportunities

The significant unmet need in oncology for tolerable, targeted therapies provides a large addressable market.
Success in the actinic keratosis indication offers a potentially faster development path and initial revenue stream to fund broader oncology trials.
The collaboration with Lonza de-risks late-stage development and provides key manufacturing expertise.

Risk Factors

High clinical development risk inherent in the historically challenging PI3K/mTOR inhibitor class, with potential for toxicity and efficacy hurdles.
Heavy reliance on a single lead candidate (bimiralisib) and the financial/strategic support of its parent company, Swiss Rockets.
Intense competition in both oncology and dermatology markets.

Competitive Landscape

Torqur competes in the crowded PI3K/mTOR inhibitor space, which includes approved drugs like alpelisib (PI3Kα) and everolimus (mTOR), as well as numerous clinical-stage candidates from other biopharma companies. In actinic keratosis, it faces established topical therapies (e.g., fluorouracil, imiquimod, diclofenac) and newer field treatments. Differentiation will require demonstrating superior efficacy, tolerability, or dosing convenience.

More companies in Small Molecule Drugs →More companies in Switzerland →